438 results on '"Bergmann, Lars"'
Search Results
2. High expression of L-GILZ transcript variant 1 (GILZ TV 1) is associated with increased 30-day sepsis mortality, and a high expression ratio possibly contraindicates hydrocortisone administration
3. Response to letter to the editor regarding “Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries”
4. Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
5. Protein Interaction Assessing Mitochondrial Biogenesis as a Next Generation Biomarker in Sepsis: A Prospective Cohort Study
6. Pathological findings associated with the updated European Society of Cardiology 2022 guidelines for preoperative cardiac testing: an observational cohort modelling study
7. Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS
8. Risk assessment for major adverse cardiovascular events after noncardiac surgery using self-reported functional capacity: international prospective cohort study
9. Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
10. Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson’s Disease
11. Intraoperative positive end-expiratory pressure and postoperative pulmonary complications: a patient-level meta-analysis of three randomised clinical trials
12. Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries
13. The impact of the COVID-19 pandemic on non-COVID induced sepsis survival
14. Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries
15. Exploring the relationship between HCMV serostatus and outcomes in COVID-19 sepsis
16. Quality of Life Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa in People with Parkinson’s (P9-3.003)
17. Improvement of “On” and “Off” Times in Patients with Advanced Parkinson’s Disease Treated with Foslevodopa/Foscarbidopa: Subgroup Analyses from a Phase 3 Randomized Study (S30.007)
18. Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on Sleep Dysfunction in People with Parkinson’s (P9-3.005)
19. Pathological findings associated with the updated European Society of Cardiology 2022 guidelines for preoperative cardiac testing: an observational cohort modelling study
20. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
21. Satisfaction with videoconferencing support for levodopa-carbidopa intestinal gel: An observational study.
22. Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.
23. Association between self-reported functional capacity and general postoperative complications: analysis of predefined outcomes of the MET-REPAIR international cohort study
24. The Aquaporin 3 Polymorphism (rs17553719) Is Associated with Sepsis Survival and Correlated with IL-33 Secretion
25. AQP3 and AQP9—Contrary Players in Sepsis?
26. Timely Cessation of Proton Pump Inhibitors in Critically Ill Patients Impacts Morbidity and Mortality: A Propensity Score-Matched Cohort Study*
27. Methazolamide Reduces the AQP5 mRNA Expression and Immune Cell Migration—A New Potential Drug in Sepsis Therapy?
28. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson’s disease: results of the Italian GLORIA patient population
29. A computational study of the effect of bond pad thickness on the polysilicon piezoresistivity due to wafer level probing
30. The Association between the rs3747406 Polymorphism in the Glucocorticoid-Induced Leucine Zipper Gene and Sepsis Survivals Depends on the SOFA Score.
31. 2611 Dyskinesia signs and symptoms, and quality of life in Parkinson’s Disease: post hoc analysis from the DYSCOVER study
32. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry
33. Mitochondrial dysfunction in sepsis is associated with diminished intramitochondrial TFAM despite its increased cellular expression
34. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
35. Characterizing a Parkinson’s Disease Population Inadequately Controlled by Oral Therapy: Baseline Characteristics of the Phase 3 Clinical Program for Foslevodopa/Foscarbidopa (P2-11.006)
36. Safety of Foslevodopa/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial (S32.004)
37. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs
38. DNA methylation of a NF-κB binding site in the aquaporin 5 promoter impacts on mortality in sepsis
39. Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients
40. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes
41. Correction to: Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study
42. Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS)
43. Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up
44. Exemplarische Anwendungsbeispiele zur ProfiL-Software
45. Anforderungen an das ProfiL-Softwarekonzept
46. ProfiL-Software zur Unterstützung der integrierten Modernisierung
47. Denken in Wertschöpfung und Verschwendung
48. Entwicklung und Formulierung der Unternehmensstrategie
49. Positionsbestimmung des Unternehmens: Interne und externe Analyse
50. Gestaltung transparenter Geschäftsprozesse
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.